On July 20, 2023, Arcadia Biosciences, Inc. announced that they are carrying out a strategic review to explore financial and strategic alternatives aimed at increasing long-term shareholder value. This followed the presentation of the company's cash equivalents as of June 30, 2023, and the expected revenue range for the second quarter of 2023.